Systems announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU ...

Part B will also cover IVIG that’s administered in a hospital, outpatient clinic, or infusion center. Depending on the condition being treated, Part B may cover both the medication and the cost ...

The SCIg market is growing rapidly, with KORU Medical Systems outperforming competitors by capturing market share. Read why I ...

This latter effect is important both because therapy in CIDP is usually episodic and because IVIg is typically a more expensive treatment and indefinite monthly infusions would be quite resource ...

or IVIG, have raised concerns that symptom improvements might be due to large saline infusions in the placebo group, but ...

Systems (Nasdaq:KRMD) announced today that it signed a development agreement with a global pharmaceutical company.

The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) therapy infusion system for use with a commercialized ...

My first IVIG session went well – no side effects during the infusion, other than a headache ... a home treatment option called SCIG – for “subcutaneous IG.” It’s a shot you give ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®– (normal immunoglobulin [human] 10% and ...

KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and ...